Effect of Bempedoic Acid on Serum Uric Acid and Related Outcomes: A Systematic Review and Meta-analysis of the available Phase 2 and Phase 3 Clinical Studies
Sign Up to like & getrecommendations! Published in 2020 at "Drug Safety"
DOI: 10.1007/s40264-020-00931-6
Abstract: Introduction Bempedoic acid (ETC-1002) is a first-in-class lipid-lowering agent recently approved by the United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for commercialization. Objective The aim was to assess,… read more here.
Keywords: phase; acid; bempedoic acid; meta analysis ... See more keywords
Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of Bempedoic acid on cardiovascular events in patients with statin intolerance.
Sign Up to like & getrecommendations! Published in 2020 at "American heart journal"
DOI: 10.1016/j.ahj.2020.10.060
Abstract: BACKGROUND Although statins play a pivotal role in the prevention of atherosclerotic cardiovascular disease, many patients fail to achieve recommended lipid levels due to statin-associated muscle symptoms. Bempedoic acid is an oral pro-drug that is… read more here.
Keywords: statin intolerance; clear outcomes; trial; bempedoic acid ... See more keywords
Synthesis of Bempedoic Acid through Electrochemical Decarboxylation of Dialkylated Malonic Acid
Sign Up to like & getrecommendations! Published in 2021 at "Synthesis"
DOI: 10.1055/a-1482-9822
Abstract: Bempedoic acid is a small-molecule inhibitor of adenosine triphosphate-citrate lyase (ACL) that is effective in the treatment of hypercholesterolemia and hypertension. In this paper, a new, six-step synthesis of bempedoic acid with 42% overall yield… read more here.
Keywords: bempedoic; synthesis bempedoic; decarboxylation dialkylated; electrochemical decarboxylation ... See more keywords
Bempedoic Acid: a cholesterol lowering agent with a novel mechanism of action
Sign Up to like & getrecommendations! Published in 2021 at "Expert Review of Clinical Pharmacology"
DOI: 10.1080/17512433.2021.1901579
Abstract: ABSTRACT Introduction Dyslipidemia is a common condition that increases the risk of heart diseases and stroke. High levels of low-density lipoprotein-cholesterol (LDL-C) are correlated with a higher risk for heart disease. A drug class known… read more here.
Keywords: bempedoic acid; cholesterol; pharmacology; acid ... See more keywords
Bempedoic acid for nonalcoholic fatty liver disease: evidence and mechanisms of action.
Sign Up to like & getrecommendations! Published in 2023 at "Current opinion in lipidology"
DOI: 10.1097/mol.0000000000000878
Abstract: PURPOSE OF REVIEW Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent progressive condition that lacks a specific pharmacological treatment. ATP-citrate lyase (ACLY) is one of the emergent targets for the treatment of NAFLD. This… read more here.
Keywords: nonalcoholic fatty; liver disease; bempedoic acid; fatty liver ... See more keywords
Pharmacokinetics of Bempedoic Acid in Patients With Renal Impairment.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical and translational science"
DOI: 10.1111/cts.13202
Abstract: Bempedoic acid is an ATP citrate lyase inhibitor approved for the treatment of hypercholesterolemia. The objective of this phase 1 study was to assess the pharmacokinetics and safety of bempedoic acid in 24 subjects with… read more here.
Keywords: renal impairment; bempedoic acid; renal function;
The Disposition and Metabolism of Bempedoic Acid, a Potent Inhibitor of ATP Citrate Lyase, in Healthy Human Subjects
Sign Up to like & getrecommendations! Published in 2023 at "Drug Metabolism and Disposition"
DOI: 10.1124/dmd.122.001142
Abstract: The disposition and metabolism of bempedoic acid, a selective inhibitor of ATP citrate lyase, were examined in healthy male subjects. After a single administration of [14C] bempedoic acid (240 mg, 113 μCi) oral solution, mean… read more here.
Keywords: bempedoic; bempedoic acid; disposition metabolism;
Prevention of Diet-Induced Metabolic Dysregulation, Inflammation, and Atherosclerosis in Ldlr−/− Mice by Treatment With the ATP-Citrate Lyase Inhibitor Bempedoic Acid
Sign Up to like & getrecommendations! Published in 2017 at "Arteriosclerosis, Thrombosis, and Vascular Biology"
DOI: 10.1161/atvbaha.116.308963
Abstract: Objective— Bempedoic acid (ETC-1002, 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid) is a novel low-density lipoprotein cholesterol–lowering compound. In animals, bempedoic acid targets the liver where it inhibits cholesterol and fatty acid synthesis through inhibition of ATP-citrate lyase and through… read more here.
Keywords: bempedoic acid; bempedoic; diet induced; treatment ... See more keywords
Abstract 13130: Efficacy and Safety of Bempedoic Acid by Sex: Pooled Analyses From Phase 3 Trials
Sign Up to like & getrecommendations! Published in 2020 at "Circulation"
DOI: 10.1161/circ.142.suppl_3.13130
Abstract: Introduction: Bempedoic acid (BA), an ATP-citrate lyase inhibitor, lowers low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia. Objective: To report efficacy and safety... read more here.
Keywords: efficacy safety; bempedoic acid; abstract 13130;
Simulation study on LDL cholesterol target attainment, treatment costs, and ASCVD events with bempedoic acid in patients at high and very-high cardiovascular risk
Sign Up to like & getrecommendations! Published in 2022 at "PLOS ONE"
DOI: 10.1371/journal.pone.0276898
Abstract: Background and aims The LDL cholesterol (LDL-C) treatment goals recommended by the 2019 ESC/EAS guidelines are only achieved in a minority of patients. The study objective was to estimate the impact of bempedoic acid treatment… read more here.
Keywords: bempedoic acid; risk; ascvd events; treatment ... See more keywords
The effect of bempedoic acid an ATP-citrate lyase inhibitor on cardiovascular risk factors in rats with experimentally induced myocardial infarction and hyperlipidemia.
Sign Up to like & getrecommendations! Published in 2022 at "Cellular and molecular biology"
DOI: 10.14715/cmb/2022.68.10.15
Abstract: Control of hyperlipidemia is believed to reduce major cardiovascular events such as cardiovascular death, myocardial infarction, nonfatal stroke, hospitalization for unstable angina, and coronary revascularization. The benefits of monotherapy with Bempedoic acid (BA) as a… read more here.
Keywords: hyperlipidemia; myocardial infarction; group; bempedoic acid ... See more keywords